Abstract:The clinical benefits of current antioxidant therapy for Alzheimer's disease (AD) are limited due to their poor disease target specificity. Our long-term objective is thus to design target-specific antioxidants and better understand their pharmacological mechanisms for AD and other human diseases, based on an emerging “pharmacophore conjugation” concept for drug development. The specific hypothesis for this studyl is that amyloid-targeting antioxidants assume targeted interdictions against cerebral Aβ amyloid pathology. We have rationally designed, synthesized, and characterized a novel bifunctional antioxidant- XH2A with chemically conjugated amyloid binding (benzothiazole) and antioxidant (lipoate) moieties. We have performed in sillico, cell culture and animal studies to characterize its partial pharmacological properties. In sillico, cellular, and animal studies on XH2A indicated that: (i) XH2A molecule has only one NH group (<5 hydrogen-bond donors), two N and one O atoms (<10 hydrogen bond acceptors), MW=414 (<500). It agrees well with the general Lipinski's Rule of Five; (ii) XH2A interacts with Aβ1-40 peptide computationally and has an affinity binding constant of KD=4.43 μM toward monomeric Aβ1-40 peptide as determined by the SPR (surface plasmon resonance) technique; (iii) XH2A has no neurotoxicity at low micromolar concentrations, and it interdicted amyloid precursor protein (APP) translation (via its 5'UTR, IC50=50 nM) in human SH-SY5Y cells and attenuated cerebral Aβ amyloid pathology in PS1/APP doubly transgenic mice without inducing apparent animal toxicity and behavior disturbances; (iv) BBB penetration studies indicated that XH2A brain concentration can reach 16 nM (via oral route, a single gavage dose of 25 mg/kg) in mouse brain in just 2 hours. This is approximately 32% of its IC50=50 nM, and its brain to plasma concentration ratio is around 1:2. XH2A interdicts Alzheimer's Aβ amyloidosis both in vitro and in vivo. Thus, XH2A could be a novel brain-permeable antioxidant targeting Alzheimer's amyloidosis.

Analysis of the interaction of para-sulfonatocalix[8]arene with free amino acids and a six residue segment of β-amyloid peptide as a potential treatment for Alzheimer’s disease

Inhibitor discovery targeting the intermediate structure of β-amyloid peptide on the conformational transition pathway: Implications in the aggregation mechanism of β-amyloid peptide

Molecular engineering of a theranostic molecule that detects Aβ plaques, inhibits Iowa and Dutch mutation Aβ self-aggregation and promotes lysosomal biogenesis for Alzheimer's disease

Syringic acid demonstrates promising protective effect against tau fibrillization and cytotoxicity through regulation of endoplasmic reticulum stress-mediated pathway as a prelude to Alzheimer's disease

Mechanism Exploration of Amyloid-β-42 Disaggregation by Single-Chain Variable Fragments of Alzheimer’s Disease Therapeutic Antibodies

Mechanism Exploration of Amyloid-β-42 Disaggregation by Single-Chain Variable Fragments of Alzheimer's Disease Therapeutic Antibodies.

Sesamol as a potential small molecule in inhibiting the induction of neurotoxic amyloids fibrils involved in the pathophysiology of alzheimer's disease

SKGQA, a Peptide Derived from the ANA/BTG3 Protein, Cleaves Amyloid-β with Proteolytic Activity

Computational Study of Natural Compounds for the Clearance of Amyloid-Βeta: A Potential Therapeutic Management Strategy for Alzheimer’s Disease

Impact of Alternating Amino Acid Sequences on Beta-Amyloid-induced Neurotoxicity and Neuroinflammation in Alzheimer's Disease.

Covalent immobilization of human serum albumin on cellulose acetate membrane for scavenging amyloid beta – A stepping extracorporeal strategy for ameliorating Alzheimer's disease

Molecular-Level Examination of Cu2+ Binding Structure for Amyloid Fibrils of 40-Residue Alzheimer’s Β by Solid-State NMR Spectroscopy

Inhibition behavior of Sennoside A and Sennoside C on amyloid fibrillation of human lysozyme and its possible mechanism

Targeting the Amyloid-β Fibril Surface with a Constrained Helical Peptide Inhibitor.

Compilation and Analysis of Enzymes, Engineered Antibodies, and Nanoparticles Designed to Interfere with Amyloid-Beta Aggregation

A BBB-permeable Antioxidant Targeting Alzheimer's Amyloidogenesis

Synthesis and evaluation of ferrocenoyl pentapeptide (Fc-KLVFF) as an inhibitor of Alzheimer's Aβ₁-₄₂ fibril formation in vitro

Investigation of supramolecular structures in various aqueous solutions of an amyloid forming peptide using small-angle X-ray scattering

Evaluation of Natural Flavonoid Compounds in Amyloid-β (Aβ) Inhibition for Alzheimer’s Disease Treatment

Charged Tubular Supramolecule Boosting Multivalent Interactions for the Drastic Suppression of Aβ Fibrillation

An 11-mer Synthetic Peptide Suppressing Aggregation of Aβ25-35 and Resolving Its Aggregated Form Improves Test Performance in an Aβ25-35-Induced Alzheimer's Mouse Model